Survival data firms up Trodelvy prospects in new breast cancer use Sacituzumab govitecan - Gilead Sciences - Metastasis - Metastatic breast cancer.

Gilead Sciences confirms it has filed for approval of Trop2 drug Trodelvy in HR /HER2- advanced breast cancer, as updated results from the TROPICS-02 study show an improvement in overall survival.

Read more at pharmaphorum

Targeted therapy for genetic breast cancer gets approval Non-small cell lung cancer - Food and Drug Administration - HER2/neu - AstraZeneca.

A doctor with Sylvester Comprehensive Cancer is a principal investigator for a newly approved breast cancer drug.

Read more at WPLG Local 10

Molecular Changes in Triple-Negative Breast Cancers Have Been Revealed Triple-negative breast cancer - Metastasis - HER2/neu - Oncology.

TNBC is affected by the absence of expression of human epidermal growth factor receptor 2 (Her2-neu), estrogen receptor, or progesterone receptors. Many current breast cancer therapies are using these receptors, thus they are of little benefit to those ...

Read more at List23

FDA Approves First Targeted Therapy for HER2-Low Breast Cancer Breast cancer - AstraZeneca - Food and Drug Administration - HER2/neu.

August 8, 2022 — The U.S. Food and Drug Administration approved Enhertu (fam-trastuzumab-deruxtecan-nxki), an IV infusion for the treatment of patients with unresectable (unable to be removed) or metastatic (spread to other parts of the body) HER2-low ...

Read more at Imaging Technology News